异基因造血干细胞移植后急性呼吸窘迫综合征患者接受体外膜氧合治疗的特征与结局
这项多中心回顾性观察研究纳入2010至2015年间12个欧洲三级中心ICU中因ARDS接受静脉-静脉体外膜氧合(VV-ECMO)的37例异基因造血干细胞移植受者。ICU入住中位时间为移植后146天(四分位距27-321天),ARDS主要原因为肺炎(81%)。总体出院存活率为19%(7例),随访18个月(范围5-30个月)时均存活且血液病缓解。移植后240天内启动ECMO者24例中仅1例(4%)存活,而240天后启动者13例中6例(46%)存活(p<0.01)。14例(38%)发生出血事件,其中6例(16%)与死亡相关。
要点
- 移植后240天内启动VV-ECMO的24例中仅1例(4%)存活,而240天后启动的13例中6例(46%)存活(p<0.01)。
- 总体出院存活率为19%(7/37),随访18个月(范围5-30个月)时均存活且血液病缓解。
- ARDS主要病因为肺炎(81%),ICU入住中位时间为移植后146天(四分位距27-321天)。
- ECMO启动时接受无创通气的9例中,除1例外其余均随后插管。
- 出血事件发生于14例(38%),其中6例(16%)与死亡相关。
适用人群与场景
- 2010至2015年间,12个欧洲三级中心(奥地利、德国、法国、比利时)ICU中因ARDS接受静脉-静脉体外膜氧合(VV-ECMO)的所有异基因造血干细胞移植受者。
- 共37例,其中9例在ECMO启动时接受无创通气。
研究设计与关键结果
- 多中心回顾性观察研究,纳入37例异基因造血干细胞移植后因ARDS接受VV-ECMO的患者,主要原因为肺炎(81%)。
- ICU入住中位时间为移植后146天(四分位距27-321天)。
- 总体出院存活率为19%(7/37),随访18个月(范围5-30个月)时均存活且血液病缓解。
- 移植后240天内启动ECMO者24例中仅1例(4%)存活,而240天后启动者13例中6例(46%)存活(p<0.01)。
- ECMO启动时接受无创通气的9例中,除1例外其余均随后插管。
- 出血事件发生于14例(38%),其中6例(16%)与死亡相关。
证据类型、等级与局限
- 证据类型:多中心回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,移植后早期(240天内)因ARDS启动ECMO的存活率令人沮丧,不支援该组使用ECMO。
- 作者认为,移植后晚期且其他方面适合全代码ICU管理的受者,在严重ARDS常规措施失败时可能是ECMO治疗的潜在候选者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The acute respiratory distress syndrome is a frequent condition following allogeneic hematopoietic stem cell transplantation. Extracorporeal membrane oxygenation may serve as rescue therapy in refractory acute respiratory distress syndrome but has not been assessed in allogeneic hematopoietic stem cell transplantation recipients.
DESIGN: Multicenter, retrospective, observational study.
SETTING: ICUs in 12 European tertiary care centers (Austria, Germany, France, and Belgium).
PATIENTS: All allogeneic hematopoietic stem cell transplantation recipients treated with venovenous extracorporeal membrane oxygenation for acute respiratory distress syndrome between 2010 and 2015.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Thirty-seven patients, nine of whom underwent noninvasive ventilation at the time of extracorporeal membrane oxygenation initiation, were analyzed. ICU admission occurred at a median of 146 (interquartile range, 27-321) days after allogeneic hematopoietic stem cell transplantation. The main reason for acute respiratory distress syndrome was pneumonia in 81% of patients. All but one patient undergoing noninvasive ventilation at extracorporeal membrane oxygenation initiation had to be intubated thereafter. Overall, seven patients (19%) survived to hospital discharge and were alive and in remission of their hematologic disease after a follow-up of 18 (range, 5-30) months. Only one of 24 patients (4%) initiated on extracorporeal membrane oxygenation within 240 days after allogeneic hematopoietic stem cell transplantation survived compared to six of 13 (46%) of those treated thereafter (p < 0.01). Fourteen patients (38%) experienced bleeding events, of which six (16%) were associated with fatal outcomes.
CONCLUSIONS: Discouraging survival rates in patients treated early after allogeneic hematopoietic stem cell transplantation do not support the use of extracorporeal membrane oxygenation for acute respiratory distress syndrome in this group. On the contrary, long-term allogeneic hematopoietic stem cell transplantation recipients otherwise eligible for full-code ICU management may be potential candidates for extracorporeal membrane oxygenation therapy in case of severe acute respiratory distress syndrome failing conventional measures.
参考来源
- Wohlfarth P, Beutel G, Lebiedz P, et al. Characteristics and Outcome of Patients After Allogeneic Hematopoietic Stem Cell Transplantation Treated With Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome. Crit Care Med. 2017. PMID: 28410318. doi:10.1097/CCM.0000000000002293
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。